Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gates Commits $89m To Novavax After Maternal RSV Vaccine Success

This article was originally published in Scrip

Executive Summary

Now that Novavax Inc.'s respiratory syncytial virus (RSV) vaccine has succeeded in a Phase II clinical trial in pregnant women, the Bill & Melinda Gates Foundation has committed up to $89m to help the company fund a massive Phase III trial that will include sites in developing countries.

Advertisement

Related Content

FDA Panel To Weigh Animal, Adult Human Data For Initiation Of RSV Vaccine Trials In Infants
Novavax’s Phase III RSV Vaccine Failure Wipes Out Nearly $2bn In Value
Case Studies: How Three Public Companies Financed R&D In A Tough Market

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC029894

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel